Galanin function in the central nervous system

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 5, 2006, Pages 560-570

  Walton, Kevin M ^a   Chin, Janice E ^a   Duplantier, Allen J ^a   Mather, Robert J ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Anxiety; Cognition; Depression; Neuroprotection; Obesity; Seizure

Indexed keywords

2 DIBUTYLAMINO 8 HYDROXYTETRALIN; ARM 1896; GALANIN; GALMIC; GALNON; M 35; M 40; MUSCARINIC M1 RECEPTOR AGONIST; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PROTEIN INHIBITOR; RWJ 57408; SCH 202596; SNAP 37889; SNAP 398299; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANXIETY; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG BINDING; DRUG INHIBITION; DRUG STRUCTURE; FOOD INTAKE; LEARNING; MEMORY; NERVE FUNCTION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REVIEW; SEIZURE;

ALZHEIMER DISEASE; ANIMALS; ANXIETY; CENTRAL NERVOUS SYSTEM; DEPRESSION; GALANIN; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 33748596852     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Tatemoto K, Rokaeus A, Jornvall H, McDonald TJ, Mutt V: Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett (1983) 164(1):124-128.
2. Rokaeus A, Melander T, Hokfelt T, Lundberg JM, Tatemoto K, Carlquist M, Mutt V: A galanin-like peptide in the central nervous system and intestine of the rat. Neurosci Lett (1984) 47(2):161-166.
3. Melander T, Hokfelt T, Rokaeus A, Cuello AC, Oertel WH, Verhofstad A, Goldstein M: Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J Neurosci (1986) 6(12):3640-3654.
4. Melander T, Hokfelt T, Rokaeus A, Fahrenkrug J, Tatemoto K, Mutt V: Distribution of galanin-like immunoreactivity in the gastrointestinal tract of several mammalian species. Cell Tissue Res (1985) 239(2):253-270.
5. Melander T, Staines WA, Hokfelt T, Rokaeus A, Eckenstein F, Salvaterra PM, Wainer BH: Galanin-like immunoreactivity in cholinergic neurons of the septum-basal forebrain complex projecting to the hippocampus of the rat. Brain Res (1985) 360(1-2):130-138.
6. Xu ZQ, Shi TJ, Hokfelt T: Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J Comp Neurol (1998) 392(2):227-251.
7. Benzing WC, Kordower JH, Mufson EJ: Galanin immunoreactivity within the primate basal forebrain: Evolutionary change between monkeys and apes. J Comp Neurol (1993) 336(1):31-39.
8. Gentleman SM, Falkai P, Bogerts B, Herrero MT, Polak JM, Roberts GW: Distribution of galanin-like immunoreactivity in the human brain. Brain Res (1989) 505(2):311-315.
9. Vogels OJ, Renkawek K, Broere CA, ter Laak HJ, van Workum F: Galanin-like immunoreactivity within Ch2 neurons in the vertical limb of the diagonal band of Broca in aging and Alzheimer's disease. Acta Neuropathol (1989) 78(1):90-95.
10. Chan-Palay V: Neurons with galanin innervate cholinergic cells in the human basal forebrain and galanin and acetylcholine coexist. Brain Res Bull (1988) 21(3):465-472.
11. Vrontakis ME, Peden LM, Duckworth ML, Friesen HG: Isolation and characterization of complementary DNA (galanin) clone from estrogen-induced pituitary tumor messenger RNA. J Biol Chem (1987) 262(35):16755-16758.
12. Rokaeus A, Brownstein MJ: Construction of a porcine adrenal medullary cDNA library and nucleotide sequence analysis of two clones encoding a galanin precursor. Proc Natl Acad Sci USA (1986) 83(17):6287-6291.
13. McKnight GL, Karlsen AE, Kowalyk S, Mathewes SL, Sheppard PO, O'Hara PJ, Taborsky GJ Jr: Sequence of human galanin and its inhibition of glucose-stimulated insulin secretion from RIN cells. Diabetes (1992) 41(1):82-87.
14. + channels. J Biol Chem (1998) 273(36):23321-23326.
15. Kolakowski LF Jr, O'Neill GP, Howard AD, Broussard SR, Sullivan KA, Feighner SD, Sawzdargo M, Nguyen T, Kargman S, Shiao LL, Hreniuk DL et al: Molecular characterization and expression of cloned human galanin receptors GalR2 and GalR3. J Neurochem (1998) 71(6):2239-2251.
16. Pang L, Hashemi T, Lee HJ, Maguire M, Graziano MP, Bayne M, Hawes B, Wong G, Wang S: The mouse GalR2 galanin receptor: Genomic organization, cDNA cloning, and functional characterization. J Neurochem (1998) 71(6):2252-2259.
17. Smith KE, Forray C, Walker MW, Jones KA, Tamm JA, Bard J, Branchek TA, Linemeyer DL, Gerald C: Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem (1997) 272(39):24612-24616.
18. Howard AD, Tan C, Shiao LL, Palyha OC, McKee KK, Weinberg DH, Feighner SD, Cascieri MA, Smith RG, Van Der Ploeg LH, Sullivan KA: Molecular cloning and characterization of a new receptor for galanin. FEBS Lett (1997) 405(3):285-290.
19. Wang S, Hashemi T, He C, Strader C, Bayne M: Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol (1997) 52(3):337-343.
20. Parker EM, Izzarelli DG, Nowak HP, Mahle CD, Iben LG, Wang J, Goldstein ME: Cloning and characterization of the rat GalR1 galanin receptor from Rin14B insulinoma cells. Brain Res Mol Brain Res (1995) 34(2):179-189.
21. Habert-Ortoli E, Amiranoff B, Loquet I, Laburthe M, Mayaux JF: Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci USA (1994) 91(21):9780-9783.
22. Deecher DC, Mash DC, Staley JK, Mufson EJ: Characterization and localization of galanin receptors in human entorhinal cortex. Regul Pept (1998) 73(3):149-159.
23. O'Donnell D, Ahmad S, Wahlestedt C, Walker P: Expression of the novel galanin receptor subtype GalR2 in the adult rat CNS: Distinct distribution from GalR1. J Comp Neurol (1999) 409(3):469-481
24. Burazin TC, Larm JA, Ryan MC, Gundlach AL: Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. Eur J Neurosci (2000) 12(8):2901-2917.
25. Mennicken F, Hoffert C, Pelletier M, Ahmad S, O'Donnell D: Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system. J Chem Neuroanat (2002) 24(4):257-268.
26. Lang R, Berger A, Santic R, Geisberger R, Hermann A, Herzog H, Kofler B: Pharmacological and functional characterization of galanin-like peptide fragments as potent galanin receptor agonists. Neuropeptides (2005) 39(3):179-184.
27. Wang S, Hashemi T, Fried S, Clemmons AL, Hawes BE: Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry (1998) 37(19):6711-6717,
28. Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T: The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to Gq, Gi and G12 proteins. Oncogene (2000) 19(37):4199-4209.
29. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR: Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 10(2):122-126.
30. Wilcock GK, Esiri MM, Bowen DM, Smith CC: Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci (1982) 57(2-3):407-417.
31. Cummings JL, Kaufer D: Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology (1996) 47(4):876-883.
32. Chan-Palay V: Hyperinnervation of surviving neurons of the human basal nucleus of Meynert by galanin in dementias of Alzheimer's and Parkinson's disease. Adv Neurol (1990) 51:253-255. Early description of hypertrophy and hyperinnervation of galanin in Alzheimer's disease and provides model for role of galanin in cognitive deficits.
33. Maxwell L, Maxwell DJ, Neilson M, Kerr R: A confocal microscopic survey of serotoninergic axons in the lumbar spinal cord of the rat: Co-localization with glutamate decarboxylase and neuropeptides. Neuroscience (1996) 75(2):471-480.
34. Minami M, Makino Y, Arai H, Iizuka R: A disorganized increase of galanin-like immunoreactivity in cerebral cortex of Alzheimer-type dementia brains. J Neurol Transm Parkinsons Dis Dementia Sect (1991) 3(4):285-292.
35. Barbelivien A, Vaussy C, Marchalant Y, Maubert E, Bertrand N, Beley A, Roussel S, Mackenzie ET, Dauphin F: Degeneration of the basalocortical pathway from the cortex induces a functional increase in galaninergic markers in the nucleus basalis magnocellularis of the rat. J Cerebral Blood Flow Metab (2004) 24(11):1255-1266.
36. Beal MF, MacGarvey U, Swartz KJ: Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease. Ann Neurol (1990) 28(2):157-161.
37. Gabriel SM, Bierer LM, Davidson M, Purohit DP, Perl DP, Harotunian V: Galanin-like immune-reactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem (1994) 62(4):1516-1523.
38. Counts SE, Chen EY, Che S, Ikonomovic MD, Wuu J, Ginsberg SD, Dekosky ST, Mufson EJ: Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 21(4):205-214.
39. Bowser R, Kordower JH, Mufson EJ: A confocal microscopic analysis of galaninergic hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease. Brain Pathol (1997) 7(2):723-730.
40. Holets VR, Hokfelt T, Rokaeus A, Terenius L, Goldstein M: Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus. Neuroscience (1988) 24(3):893-906.
41. Miller MA, Kolb PE, Leverenz JB, Peskind ER, Raskind MA: Preservation of noradrenergic neurons in the locus ceruleus that coexpress galanin mRNA in Alzheimer's disease. J Neurochem (1999) 73(5):2028-2036.
42. Chan-Palay V: Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog Brain Res (1991) 88:625-630.
43. 125I-galanin binding sites in Alzheimer's disease: Increases in hippocampal subfields and a decrease in the caudate nucleus. J Neurochem (1997) 68(3):1106-1113.
44. Ikeda M, Dewar D, McCulloch J: Galanin receptor binding sites in the temporal and occipital cortex are minimally affected in Alzheimer's disease. Neurosci Lett (1995) 192(1):37-40.
45. McMillan PJ, Peskind E, Raskind MA, Leverenz JB: Increased galanin receptor occupancy in Alzheimer's disease. Neurobiol Aging (2004) 25(10):1309-1314.
46. 125I-galanin binding sites despite loss of cholinergic neurons to the hippocampus in Alzheimer's disease. Brain Res (1991) 568(1-2):303-306.
47. Sendera TJ, Ma SY, Jaffar S, Kozlowski PB, Kordower JH, Mawal Y, Saragovi HU, Mufson EJ: Reduction in TrkA-immunoreactive neurons is not associated with an overexpression of galaninergic fibers within the nucleus basalis in Down's syndrome. J Neurochem (2000) 74(3):1185-1196.
48. Elvander E, Schott PA, Sandin J, Bjelke B, Kehr J, Yoshitake T, Ogren SO: Intraseptal muscarinic ligands and galanin: Influence on hippocampal acetylcholine and cognition. Neuroscience (2004) 126(3):541-557.
49. Gleason TC, Dreiling JL, Crawley JN: Rat strain differences in response to galanin on the Morris water task. Neuropeptides (1999) 33(4):265-270.
50. Kinney JW, Starosta G, Crawley JN: Central galanin administration blocks consolidation of spatial learning. Neurobiol Learn Mem (2003) 80(1):42-54.
51. Ogren SO, Kehr J, Schott PA: Effects of ventral hippocampal galanin on spatial learning and on in vivo acetylcholine release in the rat. Neuroscience (1996) 75(4):1127-1140.
52. Schott PA, Bjelke B, Ogren SO: Distribution and kinetics of galanin infused into the ventral hippocampus of the rat: Relationship to spatial learning. Neuroscience (1998) 83(1):123-136.
53. Schott PA, Hokfelt T, Ogren SO: Galanin and spatial learning in the rat Evidence for a differential role for galanin in subregions of the hippocampal formation. Neuropharmacology (2000) 39(8):1386-1403. Study showing that direct application of galanin to hippocampus inhibits acquisition in the Morris water maze and suggests a primary role for GalR2.
54. Sundstrom E, Archer T, Melander T, Hokfelt T: Galanin impairs acquisition but not retrieval of spatial memory in rats studied in the Morris swim maze. Neurosci Lett (1988) 88(3):331-335.
55. Melander T, Staines WA, Rokaeus A: Galanin-like immunoreactivity in hippocampal afferents in the rat, with special reference to cholinergic and noradrenergic inputs. Neuroscience (1986) 19(1):223-240.
56. McDonald MP, Wenk GL, Crawley JN: Analysis of galanin and the galanin antagonist M40 on delayed non-matching-to-position performance in rats lesioned with the cholinergic immunotoxin 192 IgG-saporin. Behav Neurosci (1997) 111(3):552-563.
57. McDonald MP, Willard LB, Wenk GL, Crawley JN: Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions. J Neurosci (1998) 18(13):5078-5085.
58. McDonald MP, Crawley JN: Galanin receptor antagonist M40 blocks galanin-induced choice accuracy deficits on a delayed-nonmatching-to-position task. Behav Neurosci (1996) 110(5):1025-1032.
59. Robinson JK, Crawley JN: Intraseptal galanin potentiates scopolamine impairment of delayed nonmatching to sample. J Neurosci (1993) 13(12):5119-5125. Provides evidence that increasing galanin alone may not be sufficient to affect cognition, but can exacerbate a deficit, which perhaps reflects what is occurring in Alzheimer's disease.
60. Robinson JK, Crawley JN: Intraventricular galanin impairs delayed nonmatching-to-sample performance in rats. Behav Neurosci (1993) 107(3):458-467.
61. Ukai M, Miura M, Kameyama T: Dopaminergic involvement in improving effects of dynorphin A-(1-13) on galanin-induced impairment of passive avoidance learning in mice. Hum Psychopharmacol (1997) 12(3):243-248.
62. Ukai M, Miura M, Kameyama T: Effect of galanin on passive avoidance response, elevated plus-maze learning, and spontaneous alternation performance in mice. Peptides (1995) 16(7):1283-1286.
63. Malin DH, Novy BJ, Lett-Brown AE, Plotner RE, May BT, Radulescu SJ, Crothers MK, Osgood LD, Lake JR: Galanin attenuates retention of one-trial reward learning. Life Sci (1992) 50(13):939-944.
64. Givens BS, Olton DS, Crawley JN: Galanin in the medial septal area impairs working memory. Brain Res (1992) 582(1):71-77.
65. Arletti R, Benelli A, Cavazzuti E, Bertolini A: Galantide improves social memory in rats. Pharmacol Res (1997) 35(4):317-319.
66. Hiramatsu M, Mori H, Murasawa H, Kameyama T: Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats. Br J Pharmacol (1996) 118(2):255-260.
67. 1A receptor-mediated behavioural response in the rat. Eur J Neurosci (1998) 10(4):1230-1240.
68. Miller MA, Kolb PE, Planas B, Raskind MA: Few cholinergic neurons in the rat basal forebrain coexpress galanin messenger RNA. J Comp Neurol (1998) 391(2):248-258.
69. Wang HY, Wild KD, Shank RP, Lee DH: Galanin inhibits acetylcholine release from rat cerebral cortex via a pertussis toxin-sensitive Gi protein. Neuropeptides (1999) 33(3):197-205.
70. Steiner RA, Hohmann JG, Holmes A, Wrenn CC, Cadd G, Jureus A, Clifton DK, Luo M, Gutshall M, Ma SY, Mufson EJ et al: Galanin transgenic mice display cognitive and neurochemical deficits characteristic of Alzheimer's disease. Proc Natl Acad Sci USA (2001) 98(7):4184-4189.
71. Kokaia M, Holmberg K, Nanobashvili A, Xu ZQ, Kokaia Z, Lendahl U, Hilke S, Theodorsson E, Kahl U, Bartfai T, Lindvall O et al: Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc Natl Acad Sci USA (2001) 98(24):14006-14011.
72. Kinney JW, Starosta G, Holmes A, Wrenn CC, Yang RJ, Harris AP, Long KC, Crawley JN: Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. Learn Mem (2002) 9(4):178-190.
73. Rustay NR, Wrenn CC, Kinney JW, Holmes A, Bailey KR, Sullivan TL, Harris AP, Long KC, Saavedra MC, Starosta G, Innerfield CE et al: Galanin impairs performance on learning and memory tasks: Findings from galanin transgenic and Gal-R1 knockout mice. Neuropeptides (2005) 39(3):239-243.
74. Wrenn CC, Harris AP, Saavedra MC, Crawley JN: Social transmission of food preference in mice: Methodology and application to galanin-overexpressing transgenic mice. Behav Neurosci (2003) 117(1):21-31.
75. Wrenn CC, Marriott LK, Kinney JW, Holmes A, Wenk GL, Crawley JN: Galanin peptide levels in hippocampus and cortex of galanin-overexpressing transgenic mice evaluated for cognitive performance. Neuropeptides (2002) 36(6):413-426.
76. Kuteeva E, Hokfelt T, Ogren SO: Behavioural characterisation of young adult transgenic mice overexpressing galanin under the PDGF-β promoter. Regul Pept (2005) 125(1-3):67-78.
77. Mazarati AM, Hohmann JG, Bacon A, Liu H, Sankar R, Steiner RA, Wynick D, Wasterlain CG: Modulation of hippocampal excitability and seizures by galanin. J Neurosci (2000) 20(16):6276-6281.
78. Pirondi S, Kuteeva E, Giardino L, Ferraro L, Antonelli T, Bartfai T, Ogren SO, Hokfelt T, Calza L: Behavioral and neurochemical studies on brain aging in galanin overexpressing mice. Neuropeptides (2005) 39(3):305-312.
79. Yoshitake T, Wang FH, Kuteeva E, Holmberg K, Yamaguchi M, Crawley JN, Steiner R, Bartfai T, Ogren SO, Hokfelt T, Kehr J: Enhanced hippocampal noradrenaline and serotonin release in galanin-overexpressing mice after repeated forced swimming test. Proc Natl Acad Sci USA (2004) 101(1):354-359.
80. Yoshitake T, Reenila I, Ogren SO, Hokfelt T, Kehr J: Galanin attenuates basal and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in the rat hippocampus. Neurosci Lett (2003) 339(3):239-242.
81. Massey PV, Warburton EC, Wynick D, Brown MW, Bashir ZI: Galanin regulates spatial memory but not visual recognition memory or synaptic plasticity in perirhinal cortex. Neuropharmacology (2003) 44(1):40-48.
82. O'Meara G, Coumis U, Ma SY, Kehr J, Mahoney S, Bacon A, Allen SJ, Holmes F, Kahl U, Wang FH, Kearns IR et al: Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc Natl Acad Sci USA (2000) 97(21):11569-11574.
83. Gottsch ML, Zeng H, Hohmann JG, Weinshenker D, Clifton DK, Steiner RA: Phenotypic analysis of mice deficient in the type 2 galanin receptor (GalR2). Mol Cell Biol (2005) 25(11):4804-4811.
84. Mazarati A, Lu X, Shinmei S, Badie-Mahdavi H, Bartfai T: Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience (2004) 128(2):431-441.
85. Wrenn CC, Kinney JW, Marriott LK, Holmes A, Harris AP, Saavedra MC, Starosta G, Innerfield CE, Jacoby AS, Shine J, Iismaa TP et al: Learning and memory performance in mice lacking the GalR1 subtype of galanin receptor. Eur J Neurosci (2004) 19(5):1384-1396.
86. Planas B, Kolb PE, Raskind MA, Miller MA: Nerve growth factor induces galanin gene expression in the rat basal forebrain: Implications for the treatment of cholinergic dysfunction. J Comp Neurol (1997) 379(4):563-570.
87. Brecht S, Buschmann T, Grimm S, Zimmermann M, Herdegen T: Persisting expression of galanin in axotomized mamillary and septal neurons of adult rats labeled for c-Jun and NADPH-diaphorase. Brain Res Mol Brain Res (1997) 48(1):7-16.
88. Herdegen T, Fiallos-Estrada CE, Bravo R, Zimmermann M: Colocalization and covariation of c-Jun transcription factor with galanin in primary afferent neurons and with CGRP in spinal motoneurons following transection of rat sciatic nerve. Brain Res Mol Brain Res (1993) 17(1-2):147-154.
89. Hokfelt T, Wiesenfeld-Hallin Z, Villar M, Melander T: Increase of galanin-like immunoreactivity in rat dorsal root ganglion cells after peripheral axotomy. Neurosci Lett (1987) 83(3):217-220.
90. Cortes R, Villar MJ, Verhofstad A, Hokfelt T: Effects of central nervous system lesions on the expression of galanin: A comparative in situ hybridization and immunohistochemical study. Proc Natl Acad Sci USA (1990) 87(19):7742-7746.
91. de Lacalle S, Kulkarni S, Mufson EJ: Plasticity of galaninergic fibers following neurotoxic damage within the rat basal forebrain: Initial observations. Exp Neurol (1997) 146(2):361-366.
92. Harrison PS, Henderson Z: Quantitative evidence for increase in galanin-immunoreactive terminals in the hippocampal formation following entorhinal cortex lesions in the adult rat. Neurosci Lett (1999) 266(1):41-44.
93. Holmes PV, Crawley JN: Olfactory bulbectomy increases preprogalanin mRNA levels in the rat locus coeruleus. Brain Res Mol Brain Res (1996) 36(1):184-188.
94. Hartonian I, Mufson EJ, De Lacalle S: Long-term plastic changes in galanin innervation in the rat basal forebrain. Neuroscience (2002) 115(3):787-795.
95. Shi TJ, Hua XY, Lu X, Malkmus S, Kinney J, Holmberg K, Wirz S, Ceccatelli S, Yaksh T, Bartfai T, Hokfelt T: Sensory neuronal phenotype in galanin receptor 2 knockout mice: Focus on dorsal root ganglion neurone development and pain behaviour. Eur J Neurosci (2006) 23(3):627-636.
96. Holmes FE, Mahoney S, King VR, Bacon A, Kerr NC, Pachnis V, Curtis R, Priestley JV, Wynick D: Targeted disruption of the galanin gene reduces the number of sensory neurons and their regenerative capacity. Proc Natl Acad Sci USA (2000) 97(21):11563-11568.
97. Mahoney SA, Hosking R, Farrant S, Holmes FE, Jacoby AS, Shine J, Iismaa TP, Scott MK, Schmidt R, Wynick D: The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J Neurosci (2003) 23(2):416-421
98. Pirondi S, Fernandez M, Schmidt R, Hokfelt T, Giardino L, Calza L: The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells. J Neurochem (2005) 95(3):821-833.
99. Ding X, MacTavish D, Kar S, Jhamandas JH: Galanin attenuates β-amyloid (Aβ) toxicity in rat cholinergic basal forebrain neurons. Neurobiol Dis (2006) 21(2):413-420.
100. Liu S, Lyeth BG, Hamm RJ: Protective effect of galanin on behavioral deficits in experimental traumatic brain injury. J Neurotrauma (1994) 11(1):73-82.
101. Elliott-Hunt CR, Marsh B, Bacon A, Pope R, Vanderplank P, Wynick D: Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci USA (2004) 101(14):5105-5110.
102. Haberman RP, Samulski RJ, McCown TJ: Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med (2003) 9(8):1076-1080.
103. Lin EJ, Richichi C, Young D, Baer K, Vezzani A, During MJ: Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci (2003) 18(7):2087-2092.
104. Mazarati AM: Galanin and galanin receptors in epilepsy. Neuropeptides (2004) 38(6):331-343.
105. Mazarati AM, Liu H, Soomets U, Sankar R, Shin D, Katsumori H, Langel U, Wasterlain CG: Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci (1998) 18(23):10070-10077.
106. Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf BR, Shi TS, Hokfelt T et al: Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA (2002) 99(10)7136-7141. First study to show the anti-seizure activity of a non-peptide galanin agonist.
107. Bartfai T, Lu X, Badie-Mahdavi H, Barr AM, Mazarati A, Hua XY, Yaksh T, Haberhauer G, Ceide SC, Trembleau L, Somogyi L et al: Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci USA (2004) 101(28):10470-10475.
108. Mazarati A, Lu X, Kilk K, Langel U, Wasterlain C, Bartfai T: Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci (2004) 19(12):3235-3244.
109. Kordower JH, Le HK, Mufson EJ: Galanin immunoreactivity in the primate central nervous system. J Comp Neurol (1992) 319(4):479-500.
110. Kordower JH, Mufson EJ: Galanin-like immunoreactivity within the primate basal forebrain: Differential staining patterns between humans and monkeys. J Comp Neurol (1990) 294(2):281-292.
111. Kehr J, Yoshitake T, Wang FH, Razani H, Gimenez-Llort L, Jansson A, Yamaguchi M, Ogren SO: Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission. Neuropsychopharmacology (2002) 27(3):341-356.
112. Pieribone VA, Xu ZQ, Zhang X, Grillner S, Bartfai T, Hokfelt T: Galanin induces a hyperpolarization of norepinephrine-containing locus coeruleus neurons in the brainstem slice. Neuroscience (1995) 64(4):861-874.
113. Seutin V, Verbanck P, Massotte L, Dresse A: Galanin decreases the activity of locus coeruleus neurons in vitro. Eur J Pharmacol (1989) 164(2):373-376.
114. Zini S, Roisin MP, Langel U, Bartfai T, Ben-An Y: Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur J Pharmacol (1993) 245(1):1-7.
115. Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, Hokfelt T, Wolinsky TD, Konkel MJ, Chen H, Zhong H, Walker MW et al: Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA (2005) 102(48):17489-17494. First demonstration of selective GalR3 antagonists with behavioral effects.
116. Bing O, Moller C, Engel JA, Soderpalm B, Heilig M: Anxiolytic-like action of centrally administered galanin. Neurosci Lett (1993) 164(1-2):17-20.
117. Moller C, Sommer W, Thorsell A, Heilig M: Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology (1999) 21(4):507-512. First article to highlight amygdala as a site of galanin's actions in anxiety-related behaviors.
118. Kartsson RM, Holmes A, Heilig M, Crawley JN: Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice. Phamacol Biochem Behav (2005) 80(3):427-436.
119. Khoshbouei H, Cecchi M, Dove S, Javors M, Morilak DA: Behavioral reactivity to stress. Amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Phamacol Biochem Behav (2002) 71(3):407-417.
120. Khoshbouei H, Cecchi M, Morilak DA: Modulatory effects of galanin in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuropsychopharmacology (2002) 27(1):25-34.
121. Holmes A, Yang RJ, Crawley JN: Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. J Mol Neurosci (2002) 18(1-2):151-165.
122. Lu X, Barr AM, Kinney JW, Sanna P, Conti B, Behrens MM, Bartfai T: A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc Natl Acad Sci USA (2005) 102(3):874-879.
123. Holmes A, Li Q, Koenig EA, Gold E, Stephenson D, Yang RJ, Dreiling J, Sullivan T, Crawley JN: Phenotypic assessment of galanin overexpressing and galanin receptor R1 knockout mice in the tail suspension test for depression-related behavior. Psychopharmacology (2005) 178(2-3):276-285.
124. Kuteeva E, Wardi T, Hokfelt T, Ogren SO: Galanin enhances and a galanin antagonist attenuates depression-like behaviour in the rat. Eur Neuropsychopharmacol (2006): Epublished ahead of print. doi: 10.1016/j.euroneuro.2006.03.003 Demonstrates the effects of central galanin administration in rats performing a forced swim test and the reversal of these effects with non-selective galanin antagonist M35.
125. Bellido I, Diaz-Cabiale Z, Jimenez-Vasquez PA, Andbjer B, Mathe AA, Fuxe K: Increased density of galanin binding sites in the dorsal raphe in a genetic rat model of depression. Neurosci Lett (2002) 317(2):101-105.
126. Kyrkouli SE, Stanley BG, Leibowitz SF: Galanin: Stimulation of feeding induced by medial hypothalamic injection of this novel peptide. Eur J Pharmacol (1986) 122(1):159-160. First publication describing the orexigenic activity of galanin.
127. Crawley JN: The role of galanin in feeding behavior. Neuropeptides (1999) 33(5):369-375.
128. Gundlach AL: Galanin/GALP and galanin receptors: Role in central control of feeding, body weight/obesity and reproduction? Eur J Pharmacol (2002) 440(2-3):255-268.
129. Robinson JK, Bartfai T, Langel U: Galanin/GALP receptors and CNS homeostatic processes. CNS Neurol Disord - Drug Targets (2006) 5(3):327-334.
130. Smith BK, York DA, Bray GA: Chronic cerebroventricular galanin does not induce sustained hyperphagia or obesity. Peptides (1994) 15(7):1267-1272.
131. Stanley BG, Anderson KC, Grayson MH, Leibowitz SF: Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat Intake and body weight in female rats. Physiol Behav (1989) 46(2):173-177.
132. Lu X, Lundstrom L, Langel U, Bartfai T: Galanin receptor ligands. Neuropeptides (2005) 39(3):143-146.
133. Corwin RL, Robinson JK, Crawley JN: Galanin antagonists block galanin-induced feeding in the hypothalamus and amygdala of the rat. Eur J Neurosci (1993) 5(11):1528-1533.
134. Crawley JN, Robinson JK, Langel U, Bartfai T: Galanin receptor antagonists M40 and C7 block galanin-induced feeding. Brain Res (1993) 600(2):268-272.
135. Abramov U, Floren A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK, Bartfai T, Vasar E, Langel U: Regulation of feeding by galnon. Neuropeptides (2004) 38(1):55-61.
136. Ohtaki T, Kumano S, Ishibashi Y, Ogi K, Matsui H, Harada M, Kitada C, Kurokawa T, Onda H, Fujino M: Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus. J Biol Chem (1999) 274(52):37041-37045. First study to identify GALP.
137. Larm JA, Gundlach AL: Galanin-like peptide (GALP) mRNA expression is restricted to acurate nucleus of hypothalamus in adult male rat brain. Neuroendocrinology (2000) 72(2):67-71
138. Kageyama H, Takenoya F, Kita T, Hori T, Guan JL, Shioda S: Galanin-like peptide in the brain: Effects on feeding, energy metabolism and reproduction. Regul Pept (2005) 126(1-2):21-26.
139. Lawrence CB, Baudoin FM, Luckman SM: Centrally administered galanin-like peptide modifies food intake in the rat: A comparison with galanin. J Neuroendocrinol (2002) 14(11):853-860.
140. Matsumoto Y, Watanabe T, Adachi Y, Itoh T, Ohtaki T, Onda H, Kurokawa T, Nishimura O, Fujino M: Galanin-like peptide stimulates food intake in the rat. Neurosci Lett (2002) 322(1):67-69.
141. Krasnow SM, Fraley GS, Schuh SM, Baumgartner JW, Clifton DK, Steiner RA: A role for galanin-like peptide in the integration of feeding, body weight regulation, and reproduction in the mouse. Endocrinology (2003) 144(3):813-822.
142. Krasnow SM, Hohmann JG, Gragerov A, Clifton DK, Steiner RA: Analysis of the contribution of galanin receptors 1 and 2 to the central actions of galanin-like peptide. Neuroendocrinology (2004) 79(5):268-277.
143. Jureus A, Cunningham MJ, McClain ME, Clifton DK, Steiner RA: Galanin like peptide (GALP) is a target for regulation by leptin in the hypothalamus of the rat. Endocrinology (2000) 141(7):2703-2706.
144. Kumano S, Matsumoto H, Takatsu Y, Noguchi J, Kitada C, Ohtaki T: Changes in hypothalamic expression levels of galanin-like peptide in rat and mouse models support that it is a leptin-target peptide. Endocrinology (2003) 144(6):2634-2643.
145. Kuramochi M, Onaka T, Kohno D, Kato S, Yada T: Galanin-like peptide stimulates food intake via activation of neuropeptide Y neurons in the hypothalamic dorsomedial nucleus of the rat. Endocrinology (2006) 147(4):1744-1752. Recent publication characterizing the interactions between GALP and other important modulators of feeding behavior.
146. Wu WP, Hao JX, Lundstrom L, Wiesenfeld-Hallin Z, Langel U, Bartfai T, Xu XJ: Systemic galnon, a low-molecular weight galanin receptor agonist, reduces heat hyperalgesia in rats with nerve injury. Eur J Pharmacol (2003) 482(1-3):133-137.
147. Chu M, Mierzwa R, Truumees I, King A, Sapidou E, Barrabee E, Terracciano J, Patel MG, Gullo VP, Burner R: A new fungal metabolite, Sch 202596, with inhibitory activity in the galanin receptor GALR1 assay. Tetrahedron Lett (1997) 38(35):6111-6114.
148. Konkel MJ, Lagu B, Boteju LW, Jimenez H, Noble S, Walker MW, Chandrasena G, Blackburn TP, Nikam SS, Wright JL, Komberg BE et al: 3-Arylimino-2-indolones are potent and selective galanin Gal3 receptor antagonists. J Med Chem (2006) 49(13):3757-3758.
149. Konkel MJ, Packiarajan M, Chen H, Topiwala UP, Jimenez H, Talisman IJ, Coate H, Walker MW: Amino substituted analogs of 1-phenyl-3-phenylimino-2- indolones with potent galanin Gal3 receptor binding affinity and improved solubility. Bioorg Med Chem Lett (2006) 16(15):3950-3954.
150. Scott MK, Ross TM, Lee DH, Wang HY, Shank RP, Wild KD, Davis CB, Crooke JJ, Potocki AC, Reitz AB: 2,3-Dihydro-dithiin and -dithiepine-1,1,4,4- tetroxides: Small molecule non-peptide antagonists of the human galanin hGal-1 receptor. Bioorg Med Chem (2000) 8(6):1383-1391.
151. Liu HX, Brumovsky P, Schmidt R, Brown W, Payza K, Hodzic L, Pou C, Godbout C, Hokfelt T: Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci USA (2001) 98(17):9960-9964.
152. Lu X, Lundstrom L, Bartfai T: Galanin (2-11) binds to GalR3 in transfected cell lines: Limitations for pharmacological definition of receptor subtypes. Neuropeptides (2005) 39(3):165-167.
153. Mazarati AM, Baldwin RA, Shinmei S, Sankar R: In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: Implication for limbic seizures. J Neurochem (2005) 95(5):1495-1503.
154. Bartfai T, Fisone G, Langel U: Galanin and galanin antagonists: Molecular and biochemical perspectives. Trends Pharmacol Sci (1992) 13(8):312-317.